BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 9, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2001

View Archived Issues

Chronic therapy with ximelagatran for preventing stroke in patients with atrial fibrillation

Read More

Clinical hold placed on GM-611 pending analysis of animal toxicity studies

Read More

Licensing agreement signed for Chugai psoriasis therapeutic

Read More

Adipocyte-specific protein and essential hypertension

Read More

Phase I trials commence with Ilex Oncology's ILX-651 and NM-3

Read More

Progen receives U.S. approval to begin phase II trial of PI-88

Read More

MTX-HSA is superior to free MTX in a mouse model of rheumatoid arthritis

Read More

Risedronate approved in additional E.U. countries for reducing hip fractures

Read More

Synthetic halichondrin B analogues show high antitumor potency and wide therapeutic window

Read More

FDA issues nonapprovable letter for Zelnorm as IBS treatment

Read More

BLS successfully develops GMP manufacturing process for troponin I

Read More

Nonpeptide FSH mimetics useful for the treatment of infertility

Read More

New GLA-60 analogues designed at Sankyo inhibit macrophage activity

Read More

Roche and Trimeris expand partnership agreement for HIV fusion inhibitors

Read More

Inhibitors of tyrosine kinase from Merck useful as antiangiogenic agents

Read More

Reminyl shows potential for treatment of cerebrovascular disease-related dementia

Read More

Positive modulators of nicotinic receptor agonists in the AstraZeneca pipeline

Read More

Cannabinoid CB1 antagonists and their use reported by French lab

Read More

Plant extracts with significant efficacy in animal model of NIDDM

Read More

CollaGenex seeks pan-European approval for Periostat tablets

Read More

European launch of Zometa for TIH under way

Read More

Phase I/II study of ISIS-14803 shows dose-dependent viral load reductions

Read More

Role of calcineurin in cardiac hypertrophy and subsequent heart failure

Read More

Repligen extends phase II autism trial; biological markers/response to secretin relation reported

Read More

Two drugs will be reviewed by Endocrinologic and Metabolic Drugs Advisory Committee next month

Read More

Medarex and Genmab to codevelop antibody therapeutics for inflammation

Read More

Sanofi-Synthelabo designs selective CB2 antagonists

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 9, 2026.
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    Cas and effect: Merck’s phase III ripples HIF-2α space

    BioWorld
    Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 3, 2026
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

    BioWorld Science
    Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing